Home  |  Find Your Chapter  |  Get Involved  |  Advocacy/Government Affairs  |  Press Room  |  About The Society  |  Library
ABOUT MS LIVING WITH MS TREATMENTS RESEARCH HEADLINES SPECIAL EVENTS For Professionals
National Multiple Sclerosis Society  
Join The Movement
Donate Search Contact Us
 

Research

 

Bulletins

Bulletins Archive

MS Trials Alert:
Single-Dose Experimental IV Drug “RTL1000” Recruiting MS Patients at Five Sites Nationwide

February 15, 2008

 

Summary: Investigators at six sites across the United States are enrolling participants in a clinical trial evaluating the safety of a single dose of an intravenous drug called RTL1000 (Artielle ImmunoTherapeutics, Inc.) compared to inactive placebo in 36 people with relapsing-remitting or secondary-progressive multiple sclerosis.

Rationale: The immune attack on brain and spinal cord tissues in MS is thought to be launched by T cells that are directed at protein components of the myelin sheath that insulates nerve fibers. Over several years, Arthur Vandenbark, PhD, and colleagues have been attempting to create treatments for MS based on blocking interactions between T cells and myelin, with funding from the National MS Society. To this end, Dr. Vandenbark’s team developed molecules called recombinant TCR ligands (RTLs), which are designed to inhibit the ability of specific T cells to bind to and cause damage to myelin. Artielle ImmunoTherapeutics, Inc., is developing one of these molecules, RTL1000, as a potential treatment for MS.

Eligibility and Details: To be considered for participation in the 3-month study, individuals must be 18-65 years of age with definite relapsing-remitting MS (a course of MS characterized by clearly defined flare-ups followed by partial or complete recovery periods), or secondary-progressive MS (disease that starts with a relapsing-remitting course and then transitions to a steadily worsening disease course with or without occasional flare-up). There are other specific inclusion criteria.

The primary outcome of this study is to evaluate the safety profile of a single intravenous dose of RTL1000, and to determine the maximum tolerated dose of RTL1000 that can be given as a single dose. Secondary goals include the evaluation of the drug’s pharmacokinetics (how the drug is absorbed in the body) and the feasibility of assessing the drug’s effects on immune system activity.

Enrollment Information: Six sites are currently enrolling patients. For information, contact the site in your local area:

1)   Sarah Henry

Yale Center for MS Treatment and Research

New Haven, CT

(203) 764-8160

2)   Lee Hayward

Indiana University

Indianapolis, IN

          (317) 278-7293

3)   Lisa Schmidt

University of Kansas Medical Center

Kansas City, KS

(913) 588-3968

4)  Kerry Naunton  
     University of Maryland School of MedicineBaltimore

     (410) 328-1155   

5) Stacey Schroeder-Moultrie

MS Center of Oregon Health & Science University

Portland, OR

(503) 494-7236

6)     Yuriko Courtney

MS Center Evergreen

Kirkland, WA

(425) 899-5373

 

-- Research and Clinical Programs Department

 

* To view or print a PDF file, Adobe Acrobat Reader is required.

 

FAQsGlossary of MS Terms  


ChatMessage Boards
Email This PagePrint This Page
Home | MS Learn Online Webcasts | Spotlight Series | Información en español | Site Map

National Multiple Sclerosis Society | 1-800-344-4867

© 2007 The National Multiple Sclerosis Society. All rights reserved. Legal Notice/Privacy Policy | Powered by Convio